Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03171194 · ClinicalTrials.gov registry record · Phase 1
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03171194: Completed Phase 1 study, sponsored by Medical University of South Carolina.
NCT03171194 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03171194, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).
Primary Outcome
The primary outcome measure is the frequency of Grade 3 or higher adverse events (AEs) experienced by participants at or prior to Week 24.
Interventions
- DRUG Low Dose Mesenchymal Stem Cells (MSCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-04-27 |
| Est. Completion | 2018-10-25 |
| Phase | Phase 1 |
What the finished NCT03171194 record still lists
NCT03171194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Low Dose Mesenchymal Stem Cells (MSCs) is the first listed.
NCT03171194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03171194 about?
NCT03171194 is a clinical study titled "Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus". The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).
What is the current status of trial NCT03171194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-04-27. Estimated completion is 2018-10-25.
What interventions are being tested in trial NCT03171194?
The interventions under investigation include: Low Dose Mesenchymal Stem Cells (MSCs) (DRUG).
Who is sponsoring clinical trial NCT03171194?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03171194's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI